Serum MMP7, MMP10 and MMP12 Level As Negative Prognostic Markers in Colon Cancer Patients

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2016 Jul 20

PMID 27431388

Citations 53

Authors

Fee Klupp

Lena Neumann

Christoph Kahlert

Johannes Diers

Niels Halama

Clemens Franz

Thomas Schmidt

Moritz Koch

Juergen Weitz

Martin Schneider

Alexis Ulrich

Affiliations

Soon will be listed here.

Abstract

Background: Matrixmetalloproteinases (MMPs) comprise a family of zinc-dependent endopeptidases which are involved in angiogenesis, tumor invasion and metastatic formation. Up to date, the prognostic relevance of MMPs in serum of patients with colon cancer remains unknown. Thus, we wanted to assess an expression pattern of MMPs in a homogenous cohort of colon cancer patients to assess their potential as prognostic biomarkers.

Methods: Differences in the expression pattern of MMP7, MMP10 and MMP12 in 78 serum specimens of patients with an adenocarcinoma of the colon and serum specimens of a healthy control group were assessed using Luminex-100 technologies. Subsequently, we correlated these results with histopathological and clinical data of the patients.

Results: Luminex based expression analysis revealed a significant overexpression of MMP7 and an overexpression of MMP10 and MMP12 in the sera of colon cancer patients compared to the healthy control group. Patients with vascular invasion showed a significantly higher MMP12 expression than V0-staged patients. Moreover overexpression of MMP7, MMP10 and MMP12 in colon cancer patients´ sera displayed a significantly impaired overall survival. Multivariate analysis revealed high MMP10 serum levels to be an independent adverse prognostic marker in colon cancer patients.

Conclusions: Expression patterns of MMP7, MMP10 and MMP12 in colon cancer patients´ sera are different compared to serum specimens of healthy individuals. Furthermore, overexpression of MMP7, MMP10 and MMP12 in colon cancer patients´ sera correlates with a dismal prognosis and may help to stratify patients into different risk groups.

Citing Articles

Identification of Novel lncRNAs Related to Colorectal Cancer Through Bioinformatics Analysis.

Heidari R, Assadollahi V, Marashi S, Elahian F, Mirzaei S Biomed Res Int. 2025; 2025:5538575.

PMID: 39949372 PMC: 11824705. DOI: 10.1155/bmri/5538575.

Non-cell autonomous regulation of cell-cell signaling and differentiation by mitochondrial ROS.

Du Y, Wang L, Perez-Castro L, Conacci-Sorrell M, Sieber M J Cell Biol. 2024; 223(12.

PMID: 39535785 PMC: 11561560. DOI: 10.1083/jcb.202401084.

Structure optimization and molecular dynamics studies of new tumor-selective -triazines targeting DNA and MMP-10/13 for halting colorectal and secondary liver cancers.

Morcos C, Haiba N, Bassily R, Abu-Serie M, El-Yazbi A, Soliman O J Enzyme Inhib Med Chem. 2024; 39(1):2423174.

PMID: 39513468 PMC: 11552285. DOI: 10.1080/14756366.2024.2423174.

Unveiling the power of flavonoids: A dynamic exploration of their impact on cancer through matrix metalloproteinases regulation.

Rajendran P Biomedicine (Taipei). 2024; 14(2):12-28.

PMID: 38939095 PMC: 11204124. DOI: 10.37796/2211-8039.1447.

A decentralized federated learning-based cancer survival prediction method with privacy protection.

Chai H, Huang Y, Xu L, Song X, He M, Wang Q Heliyon. 2024; 10(11):e31873.

PMID: 38845954 PMC: 11153246. DOI: 10.1016/j.heliyon.2024.e31873.

References

Nadal C, Maurel J, Gallego R, Castells A, Longaron R, Marmol M . FAS/FAS ligand ratio: a marker of oxaliplatin-based intrinsic and acquired resistance in advanced colorectal cancer. Clin Cancer Res. 2005; 11(13):4770-4. DOI: 10.1158/1078-0432.CCR-04-2119. View

Pryczynicz A, Gryko M, Niewiarowska K, Dymicka-Piekarska V, Ustymowicz M, Hawryluk M . Immunohistochemical expression of MMP-7 protein and its serum level in colorectal cancer. Folia Histochem Cytobiol. 2013; 51(3):206-12. DOI: 10.5603/FHC.2013.0029. View

Maurel J, Nadal C, Garcia-Albeniz X, Gallego R, Carcereny E, Almendro V . Serum matrix metalloproteinase 7 levels identifies poor prognosis advanced colorectal cancer patients. Int J Cancer. 2007; 121(5):1066-71. DOI: 10.1002/ijc.22799. View

Baker E, Bergin F, Leaper D . Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging. Br J Surg. 2000; 87(9):1215-21. DOI: 10.1046/j.1365-2168.2000.01531.x. View

Martinez-Fernandez A, Garcia-Albeniz X, Pineda E, Visa L, Gallego R, Codony-Servat J . Serum matrilysin levels predict outcome in curatively resected colorectal cancer patients. Ann Surg Oncol. 2009; 16(5):1412-20. DOI: 10.1245/s10434-009-0405-9. View

Sheu B, Hsu S, Ho H, Lien H, Huang S, Lin R . A novel role of metalloproteinase in cancer-mediated immunosuppression. Cancer Res. 2001; 61(1):237-42. View

Polistena A, Cucina A, Dinicola S, Stene C, Cavallaro G, Ciardi A . MMP7 expression in colorectal tumours of different stages. In Vivo. 2014; 28(1):105-10. View

Surlin V, Ioana M, Plesea I . Genetic patterns of metalloproteinases and their tissular inhibitors - clinicopathologic and prognostic significance in colorectal cancer. Rom J Morphol Embryol. 2011; 52(1 Suppl):231-6. View

Oh J, Takahashi R, Kondo S, Mizoguchi A, Adachi E, Sasahara R . The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell. 2001; 107(6):789-800. DOI: 10.1016/s0092-8674(01)00597-9. View

10.

Leeman M, Curran S, Murray G . New insights into the roles of matrix metalloproteinases in colorectal cancer development and progression. J Pathol. 2003; 201(4):528-34. DOI: 10.1002/path.1466. View

11.

Ting W, Chen L, Pao J, Yang Y, You B, Chang T . Genetic polymorphisms of matrix metalloproteinases and clinical outcomes in colorectal cancer patients. Int J Med Sci. 2013; 10(8):1022-7. PMC: 3691801. DOI: 10.7150/ijms.6686. View

12.

Lin Q, Chen T, Lin Q, Lin G, Lin J, Chen G . Serum miR-19a expression correlates with worse prognosis of patients with non-small cell lung cancer. J Surg Oncol. 2013; 107(7):767-71. DOI: 10.1002/jso.23312. View

13.

Paschos K, Canovas D, Bird N . Enzymatic function of multiple origins regulates the progression of colorectal cancer and the development of metastases. Hippokratia. 2009; 13(1):23-31. PMC: 2633249. View

14.

Zhang G, Miyake M, Lawton A, Goodison S, Rosser C . Matrix metalloproteinase-10 promotes tumor progression through regulation of angiogenic and apoptotic pathways in cervical tumors. BMC Cancer. 2014; 14:310. PMC: 4022983. DOI: 10.1186/1471-2407-14-310. View

15.

Koller F, Dozier E, Nam K, Swee M, Birkland T, Parks W . Lack of MMP10 exacerbates experimental colitis and promotes development of inflammation-associated colonic dysplasia. Lab Invest. 2012; 92(12):1749-59. PMC: 3510327. DOI: 10.1038/labinvest.2012.141. View

16.

Masaki T, Matsuoka H, Sugiyama M, Abe N, Goto A, Sakamoto A . Matrilysin (MMP-7) as a significant determinant of malignant potential of early invasive colorectal carcinomas. Br J Cancer. 2001; 84(10):1317-21. PMC: 2363635. DOI: 10.1054/bjoc.2001.1790. View

17.

Merkel S, Wein A, Gunther K, Papadopoulos T, Hohenberger W, Hermanek P . High-risk groups of patients with Stage II colon carcinoma. Cancer. 2001; 92(6):1435-43. DOI: 10.1002/1097-0142(20010915)92:6<1435::aid-cncr1467>3.0.co;2-n. View

18.

Zucker S, Hymowitz M, Conner C, Zarrabi H, Hurewitz A, Matrisian L . Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications. Ann N Y Acad Sci. 1999; 878:212-27. DOI: 10.1111/j.1749-6632.1999.tb07687.x. View

19.

Kushlinskii N, Gershtein E, Korotkova E, Prorokov V . Prognostic role of tumor-associated proteases in colorectal cancer. Bull Exp Biol Med. 2013; 154(3):365-9. DOI: 10.1007/s10517-013-1952-4. View

20.

VAN Nguyen S, Skarstedt M, Lofgren S, Zar N, Andersson R, Lindh M . Gene polymorphism of matrix metalloproteinase-12 and -13 and association with colorectal cancer in Swedish patients. Anticancer Res. 2013; 33(8):3247-50. View